ChromaDex Reports Third Quarter 2016 Financial Results
Nov 10, 2016 21:05 pm UTC| Business
-Company Reports Revenue of $21.2 million for first 9 months 2016 and is on track for another record revenue year-Company Reports Revenue of $5.0 million for Q3 2016-Accelerating trend of peer-reviewed research validating...
Scripps Networks Interactive Announces Quarterly Dividend
Nov 10, 2016 21:02 pm UTC| Business
KNOXVILLE, Tenn., Nov. 10, 2016 -- The Scripps Networks Interactive, Inc. (Nasdaq:SNI) board of directors has declared a quarterly dividend of 25 cents ($0.25) per share payable on December 10, 2016, to shareholders of...
Blue Buffalo Reports Third Quarter 2016 Results And Announces CEO Succession
Nov 10, 2016 21:02 pm UTC| Business
WILTON, Conn., Nov. 10, 2016 -- Blue Buffalo Pet Products, Inc. (the “Company”) (NASDAQ:BUFF), the leading natural pet food company in the United States, today announced its third quarter 2016 results. Third Quarter...
Covisint Cloud Platform Showcased at 2016 Sogeti IoT Hackathon
Nov 10, 2016 21:02 pm UTC| Business
DETROIT and SAN FRANCISCO, Nov. 10, 2016 -- Covisint Corporation (Nasdaq:COVS), the leading Cloud Platform for building Identity and Internet of Things (IoT) applications, today announced that the Covisint Cloud...
Covisint Cloud Platform Showcased at 2016 Sogeti IoT Hackathon
Nov 10, 2016 21:02 pm UTC| Business
DETROIT and SAN FRANCISCO, Nov. 10, 2016 -- Covisint Corporation (Nasdaq:COVS), the leading Cloud Platform for building Identity and Internet of Things (IoT) applications, today announced that the Covisint Cloud...
Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Nov 10, 2016 21:02 pm UTC| Business
Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanomaPhase 1 clinical trial of SNDX-6352 WALTHAM, Mass., Nov. 10, 2016 ...
Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Nov 10, 2016 21:02 pm UTC| Business
Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCORE 601 in NSCLC and melanomaPhase 1 clinical trial of SNDX-6352 WALTHAM, Mass., Nov. 10, 2016 ...